RESUMO
The introduction of combination antiretroviral therapy (cART) drastically improved performance status, immune function, and life expectancy of HIV-infected individuals. In addition, incidence of opportunistic infections and of AIDS-defining malignancies declined. Nevertheless, aggressive non-Hodgkin's lymphoma still remains the leading cause of AIDS-related deaths. The availability of cART, however, significantly improved the therapeutic options for HIV-positive patients with lymphomas. Diffuse large B-cell lymphoma, Burkitt's lymphoma, or Hodgkin lymphoma has increasingly become curable diseases. In light of these favorable developments in the treatment of HIV and HIV-associated lymphomas, reduction in treatment-associated toxicities and further improvement of outcome of patients with advanced immune suppression are major requirements for future clinical trials. This review summarizes the current treatment landscape and gives an overview on future needs in HIV-positive patients with lymphoma.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma de Burkitt/tratamento farmacológico , Infecções por HIV/tratamento farmacológico , Doença de Hodgkin/tratamento farmacológico , Linfoma Relacionado a AIDS/tratamento farmacológico , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Antineoplásicos/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Linfoma de Burkitt/diagnóstico , Linfoma de Burkitt/mortalidade , Linfoma de Burkitt/virologia , Esquema de Medicação , Cálculos da Dosagem de Medicamento , Infecções por HIV/diagnóstico , Infecções por HIV/mortalidade , Infecções por HIV/virologia , Doença de Hodgkin/diagnóstico , Doença de Hodgkin/mortalidade , Doença de Hodgkin/virologia , Humanos , Linfoma Relacionado a AIDS/diagnóstico , Linfoma Relacionado a AIDS/mortalidade , Linfoma Relacionado a AIDS/virologia , Linfoma Difuso de Grandes Células B/diagnóstico , Linfoma Difuso de Grandes Células B/mortalidade , Linfoma Difuso de Grandes Células B/virologia , Análise de Sobrevida , Resultado do TratamentoRESUMO
The asymmetric unit of the title compound, C8H10O3, contains four mol-ecules, which differ in the orientation of the hy--droxy-ethyl group [O-C-C-O torsion angles = -168.89â (17), 72.9â (2), -65.8â (2) and 71.8â (2)°], as well as the orientation of the hy-droxy H atoms. Furthermore, the crystal structure displays two different types of strong hydrogen bond. The first is between an alcohol O-H and another alcohol O atom, and the second between an alcohol O-H group and an ether O atom. Additional weak hydrogen bonds between C-H groups and ether O atoms stabilize the structure.